SEC	Form	4			
		_	_	_	_

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Washington, D.C. 20549														OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). StateMent of CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							OMB Number: 3235-0287 Estimated average burden hours per response: 0.5											
transac contrac the pur securiti to satis	chase or sale o es of the issuer fy the affirmativ ons of Rule 10b	pursuant to a written plan for f equity that is intended e defense																
1. Name and Address of Reporting Person [*] Sanders Reginald J.				2. Issuer Name and Ticker or Trading Symbol <u>EyePoint Pharmaceuticals, Inc.</u> [EYPT]							(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/08/2025								Officer (give title Other (specify below) below)					
480 PLEASANT STREET (Street) WATERTOWN MA 02472				4. lf	Line						Individual or Joint/Group Filing (Check Applicable le) Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(St	ate)	(Zip)															
		Tab	le I - Non	-Deriva	ative	See	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D		Execution Date,		e, Transaction Dispo Code (Instr. 5)		urities Acquired (A) or sed Of (D) (Instr. 3, 4 a		Beneficia Owned F	s ally ollowing	6. Owne Form: D (D) or In (I) (Instr	Direct o Indirect E 1:4) C	7. Nature of Indirect Beneficial Ownership						
							Code V	Amount	unt (A) or P		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion Price of Derivative Security Security		Exercise (Month/Day/Year) ce of ivative	Execution Date, if any		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly Di or (I)	0. wnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Options (Right to buy)	\$9.11	01/08/2025			A		80,000		(1)	01/08/2035	Common Stock	80,000	\$0.00	80,000		D		

Explanation of Responses:

1. The option becomes exercisable in three ratable annual installments beginning on January 8, 2026.

Remarks:

/s/ Ron Honig, Attorney-in-Fact 01/08/2025

٦

Г

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.